Cargando…
Flubendazole Enhances the Inhibitory Effect of Paclitaxel via HIF1α/PI3K/AKT Signaling Pathways in Breast Cancer
Paclitaxel, a natural anticancer drug, is widely recognized and extensively utilized in the treatment of breast cancer (BC). However, it may lead to certain side effects or drug resistance. Fortunately, combination therapy with another anti-tumor agent has been explored as an option to improve the e...
Autores principales: | Zhou, Yuxin, Liao, Minru, Li, Zixiang, Ye, Jing, Wu, Lifeng, Mou, Yi, Fu, Leilei, Zhen, Yongqi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10606573/ https://www.ncbi.nlm.nih.gov/pubmed/37894802 http://dx.doi.org/10.3390/ijms242015121 |
Ejemplares similares
-
Flubendazole induces mitochondrial dysfunction and DRP1-mediated mitophagy by targeting EVA1A in breast cancer
por: Zhen, Yongqi, et al.
Publicado: (2022) -
Flubendazole elicits anti-cancer effects via targeting EVA1A-modulated autophagy and apoptosis in Triple-negative Breast Cancer
por: Zhen, Yongqi, et al.
Publicado: (2020) -
PI3K/Akt and HIF-1 signaling pathway in hypoxia-ischemia
por: Zhang, Zhen, et al.
Publicado: (2018) -
Flubendazole as a macrofilaricide: History and background
por: Geary, Timothy G., et al.
Publicado: (2019) -
Expression of Glut-1, HIF-1α, PI3K and p-Akt in a case of ceruminous adenoma
por: Shen, Wan-Qin, et al.
Publicado: (2012)